CP-96021 is a potent and orally available leukotriene D4 (LTD4 Ki=34 µM) / platelet activating factor (PAF Ki=37 µM) receptor antagonist. CP-96021 has antagonist capable of simultaneously targeting two different inflammatory mediators, LTD4 and PAF. CP-96021 shows high specificity for alpha1, alpha2, beta, dopamine-2, adenosine 1, 5-HT1, H1, muscarine, µ opioid, and GABA receptors, all expressing IC50 values greater than 10 µM. CP-96021 can be used to study the pathogenesis of many inflammatory diseases such as asthma[1].
